Nimotuzumab

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) [1][2].

Product Specifications

CAS Number

[780758-10-3]

Product Name Alternative

H-R3

UNSPSC

12352203

Target

EGFR

Type

Inhibitory Antibodies

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nimotuzumab.html

Purity

96.80

Solubility

H2O

Smiles

[Nimotuzumab]

Molecular Weight

(147.58 kDa)

References & Citations

[1]Zaima Mazorra, et al. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Front Pharmacol. 2017 Jun 19;8:382.|[2]Melarkode S Ramakrishnan, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. Jan-Feb 2009;1 (1) :41-8.